- Shares of antibody discoverer AbCellera Biologics Inc. (ABCL) have fallen 80% from their all-time high as the market has thoroughly discounted its COVID-19 assets.
- The pandemic showcased AbCellera’s discovery platform, but the speed to market and royalty participation percentages were complete outliers.
- With 155 programs inked with 35 partners but only five antibodies approved or in the clinic, this busted IPO merited a deeper dive.
- A full investment analysis follows in the paragraphs below.
For further details see:
Our First Assessment Of AbCellera Biologics